Sign in
Not yet recruitingPhase 2

Semaglutide Effects on Sperm Concentration in Overweight Infertile Men

Key facts

Who runs it
Copenhagen University Hospital at Herlev
Where
Denmark1 site in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 2
People taking part
150 people, planned
Starts
Jan 2027
Expected to end
Oct 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Semaglutide (Wegovy®)
  • Placebo (saline)
Record updated
18 November 2026

Who can take part

Age
18 years to 60 years
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (24)Hide the full registry criteria

Who can take part

  • Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
  • Men 18 to 60 years of age (both inclusive) at the time of signing informed consent
  • Infertile men with at least one altered semen parameter (Sperm concentration < 16 million/mL, or percentage of motile spermatozoa < 42%, or percentage of morphologically normal spermatozoa < 4%)
  • Body mass index (BMI) ≥ 27 kg/m\^2

Who cannot take part

  • Treatment with glucagon-like peptide-1-receptor-agonist (GLP-1RA) 6 months prior to inclusion
  • Use of any prescription or non-prescription medication (apart from routine vitamins, occasional use of paracetamol, acetylsalicylic acid, or ibuprofen) which could interfere with pharmacokinetic or pharmacodynamic results, as judged by the investigator, such as: Herbal products and non-routine vitamins , Insulin, medication that may cause weight gain (including systemic corticosteroids, tricyclic antidepressants, and atypical antipsychotics), orlistat, zonisamide, topiramate, phentermine, lorcaserin, bupropion, naltrexone or other weight loss drugs. Blood pressure and lipid lowering agents (e.g., statins) drugs are allowed if treatment has been stable for ≥ 1 month prior to screening at visit 0
  • Surgery scheduled for the trial duration period, except for minor, non-gastrointestinal surgical procedures at the discretion of the investigator
  • Type 1 diabetes
  • Any disorder which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol
  • Obesity related to endocrinologic disorders (e.g., Cushing's syndrome)
  • History of pancreatitis (acute or chronic)
  • History of bariatric surgery
  • Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the investigator's opinion could interfere with the results of the trial
  • Dysregulated type 2 diabetes judged by the investigators
  • Total sperm count >80 million
  • Estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m\^2
  • Serum follicle-stimulating hormone (FSH) <2 IU/L
  • Sperm concentration < 1 million/mL
  • BMI > 50 kg/m\^2
  • Known chromosomal aberrations (except minor Y-chromosome deletions)
  • Detected cystic fibrosis transmembrane conductance regulator (CFTR) mutation
  • Daily use of morphine
  • Inability or unwillingness to perform self-injection at the screening visit (with a placebo test pen)
  • Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or co-operation during the trial, as judged by the investigator

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex
  • Obesity

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Overweight and obesity are associated with functional hypogonadism and impaired semen quality. Although lifestyle interventions may improve reproductive function, long-term adherence is often challenging. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), increasingly used to treat obesity, have shown promising effects on weight loss, testosterone levels and potentially semen quality through both direct and indirect mechanisms. However, clinical evidence regarding their effects on male fertility remains limited.

Read full original descriptionShow less

The SemenGlutide trial is a randomised, double-blinded, placebo-controlled, single-centre clinical trial investigating whether once-weekly subcutaneous semaglutide improves semen quality in overweight infertile men, compared with placebo.

The 2 groups in the trial

  • SemaglutideExisting treatment, for comparison

    Semaglutide 2.4 mg administered subcutaneously once weekly

    Treatment: Semaglutide (Wegovy®)

  • PlaceboPlacebo, for comparison

    Saline administered subcutaneously once weekly

    Treatment: Placebo (saline)

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
SemenGlutide: A Randomised Double-Blinded, Placebo-Controlled, Single-Center, Clinical Trial Comparing the Effects of S.C. Semaglutide 2.4 Mg Once-Weekly Versus Placebo on Sperm Concentration in Overweight Infertile Men
Criteria questions
Built from NCT07946796, who can take part
Record updated
18 November 2026